GSK said Wednesday that its Arexvy respiratory syncytial virus vaccine for older adults has been approved by the U.S. Food and Drug Administration for the prevention of lower respiratory tract disease.
The pharmaceutical company said the approval—based on positive Phase 3 trial data that showed exceptional efficacy in older adults—is the first for individuals age 60 years or older.
GSK said Wednesday that its Arexvy respiratory syncytial virus vaccine for older adults has been approved by the U.S. Food and Drug Administration for the prevention of lower respiratory tract disease.
The pharmaceutical company said the approval—based on positive Phase 3 trial data that showed exceptional efficacy in older adults—is the first for individuals age 60 years or older.